ALS Supportive Care Protocol

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons - the nerve cells that control voluntary muscles. As motor neurons die, the brain loses the ability to control muscle movement, leading to progressive weakness, muscle wasting, and eventually paralysis. ALS typically affects both upper and lower motor neurons, causing a combination of weakness, muscle twitching, stiffness, and atrophy.

CRITICAL: ALS is a serious, progressive disease requiring specialized neurological care at an ALS center if possible. FDA-approved treatments include riluzole (which may extend survival) and edaravone (which may slow functional decline in some patients). Comprehensive care including respiratory support, nutritional management, physical therapy, and speech therapy is essential. NO supplement has been proven to slow ALS progression. These supplements support overall health and address common deficiencies but should never replace or delay proper medical care.

* Vitamin D deficiency is very common in ALS patients and may contribute to muscle weakness. Maintaining adequate vitamin D levels supports muscle function and may have neuroprotective effects.

* Coenzyme Q10 supports mitochondrial function. Mitochondrial dysfunction is implicated in ALS, and CoQ10 has shown some promise in early studies, though large trials haven't confirmed benefit.

* Creatine supports muscle energy metabolism. While Cochrane review didn't find clear evidence of benefit in ALS, it may help maintain muscle strength in some patients.

* Omega-3 Fatty Acids have anti-inflammatory and neuroprotective properties that may support overall health in ALS patients.

* Vitamin E is an antioxidant that may help reduce oxidative stress, which is elevated in ALS.

* B Vitamins support nerve function and energy metabolism. B12 is particularly important for neurological health.

* Alpha-Lipoic Acid is an antioxidant that crosses the blood-brain barrier and may help protect neurons from oxidative damage.

* Protein Supplementation is critical in ALS because maintaining weight and muscle mass is associated with better outcomes. Many ALS patients develop swallowing difficulties that make adequate nutrition challenging.

Expected timeline: No supplement should be expected to reverse ALS progression. The focus is on maintaining quality of life, nutritional status, and overall health. ALS progression varies widely - average survival is 3-5 years from diagnosis, but some patients live much longer.

Clinical Perspective

Amyotrophic lateral sclerosis (ALS): progressive motor neuron disease affecting both upper (cortical) and lower (spinal/bulbar) motor neurons. Incidence: 2-3 per 100,000. Onset typically 55-75 years. Presentations: limb-onset (70%, focal weakness), bulbar-onset (25%, dysarthria, dysphagia), respiratory-onset (rare). El Escorial criteria for diagnosis. Pathophysiology: motor neuron degeneration, oxidative stress, mitochondrial dysfunction, glutamate excitotoxicity, protein aggregation (TDP-43, SOD1).

CRITICAL: ALS management is multidisciplinary - neurology, pulmonology, nutrition, PT/OT, speech therapy, palliative care. FDA-approved treatments: riluzole (50mg BID - modestly extends survival), edaravone (60mg IV daily x 10-14 days cycles - may slow functional decline in early ALS), sodium phenylbutyrate-taurursodiol (AMX0035). Respiratory support (NIV) is life-extending. PEG tube for nutrition when dysphagia impairs intake. NO supplement has proven disease-modifying effect. Supplements are ADJUNCTIVE for supportive care.

* Vitamin D (B-grade): VDR in motor neurons; deficiency common in ALS. Observational study: low vitamin D associated with faster decline (PMID: 24100089). Review: potential neuroprotection (PMID: 28494770). Target 40-60 ng/mL; 2000-5000 IU daily.

* CoQ10 (B-grade): Mitochondrial electron transport; antioxidant. Phase II trial: high-dose CoQ10 safe, possible slowing of decline (PMID: 15639286). Review: addresses mitochondrial dysfunction (PMID: 22940096). 300-1200mg daily. Large trial needed.

* Creatine (C-grade): Phosphocreatine energy system. Cochrane review: no clear evidence of benefit in ALS (PMID: 22119903). May still be considered for muscle support. 5-10g daily.

* Omega-3 Fatty Acids (C-grade): Anti-inflammatory; neuroprotective. Observational: higher omega-3 associated with reduced ALS risk (PMID: 25866926). 2-3g EPA+DHA daily.

* Vitamin E (C-grade): Lipid-soluble antioxidant. Clinical trial: no survival benefit but safe (PMID: 16157908). Combined with riluzole in some studies. 400-2000 IU daily.

* B Vitamins (C-grade): Nerve function support. Review: B12 important for neurological health (PMID: 22351499). B-complex with B12 1000mcg daily.

* Alpha-Lipoic Acid (C-grade): Antioxidant; crosses BBB. Review: neuroprotective mechanisms (PMID: 17927124). 600-1200mg daily.

* Protein (B-grade): Malnutrition predicts worse outcomes. Guidelines: 1.2-1.5g/kg protein (PMID: 28961345). PEG feeding when oral intake insufficient.

Biomarker targets: ALSFRS-R (functional status), FVC (respiratory function), weight/BMI, vitamin D level, swallowing assessment.

Protocol notes: Multidisciplinary ALS clinic is gold standard. Riluzole started at diagnosis. Consider edaravone in early ALS. AMX0035 newly approved. Respiratory: NIV improves survival and QOL; start when FVC <80% or symptoms. PEG tube when dysphagia causes weight loss or prolonged meals. Communication devices. Spasticity: baclofen, tizanidine. Sialorrhea: glycopyrrolate, botox. Pain management. Depression common - treat actively. Pseudobulbar affect: dextromethorphan/quinidine. Fatigue management. Exercise: moderate, avoid overexertion. Clinical trials: consider enrollment. Advance care planning early. Hospice when appropriate. Average survival 3-5 years; 10% survive >10 years. Genetic testing in familial cases (10%). Caregiver support essential.

View All Protocols